核苷类药物应用在乙型肝炎后肝硬化治疗中的临床疗效分析

Analysis of the clinical efficacy of nucleoside drugs in the treatment of liver cirrhosis after hepatitis B

目的:分析核苷类药物治疗乙型肝炎后肝硬化的临床疗效。方法:收治乙型肝炎后肝硬化患者120例,平分3组。A组接受拉米夫定治疗,B组接受阿德福韦酯治疗,C组接受恩替卡韦治疗,持续治疗1年,观察、比较患者肝功能状况、并发症等。结果:治疗后,C组肝功能指标(TBIL、AST、ALT)明显低于A组、B组,差异有统计学意义(P<0.05)。治疗后,C组HBV-DNA指标低于B组、A组,差异有统计学意义(P<0.05)。结论:建议临床治疗乙型肝炎后肝硬化疾病给予核苷类药物,肝功能改善明显,HBV-DNA载量得到降低,并发症发病率较低,和阿德福韦酯、拉米夫定药物对比,恩替卡韦的疗效更突出。

Objective:To analyze the clinical efficacy of nucleoside drugs in the treatment of liver cirrhosis after hepatitis B.Methods:120 cases of patients with liver cirrhosis after hepatitis B were selected.They were divided into the three groups on average.The group A received lamivudine treatment,the group B received adefovir treatment,and the group C received entecavir.After 1 year of continuous treatment,the liver function and complications were observed and compared.Results:After treatment,the liver function index(TBIL,AST,ALT)in the group C was significantly lower than that of the group A and the group B,and the difference was statistically significant(P<0.05).After treatment,the HBV-DNA index in the group C was lower than that of the group B and the group A,and the difference was statistically significant(P<0.05).Conclusion:It is suggested that nucleoside drugs should be given for the treatment of hepatitis B cirrhosis.The liver function will be improved obviously,the HBV-DNA load will be reduced,and the incidence of complications is low.Compared with adefovir and lamivudine,the effect of entecavir is more prominent.